Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo targets Hard-to-Treat cancers with gene mutations

NCT ID NCT03218826

First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 23 times

Summary

This early-phase study tested a new drug (AZD8186) combined with chemotherapy (docetaxel) in 23 adults with advanced solid tumors that have certain gene changes (PTEN or PIK3CB mutations). The main goal was to find the safest dose and understand side effects. Researchers hope this combination can better control tumor growth when standard treatments stop working.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IIIA PROSTATE CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland, 20892, United States

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

  • UCHealth University of Colorado Hospital

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED BREAST CARCINOMA ADVANCED MALIGNANT SOLID NEOPLASM ADVANCED PROSTATE CARCINOMA ANATOMIC STAGE III BREAST CANCER AJCC V8 ANATOMIC STAGE III BREAST CANCER AJCC V8 ANATOMIC STAGE IIIA BREAST CANCER AJCC V8 ANATOMIC STAGE IIIA BREAST CANCER AJCC V8 ANATOMIC STAGE IIIB BREAST CANCER AJCC V8 ANATOMIC STAGE IIIC BREAST CANCER AJCC V8 ANATOMIC STAGE IV BREAST CANCER AJCC V8 CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC BREAST CARCINOMA METASTATIC MALIGNANT SOLID NEOPLASM METASTATIC PROSTATE CARCINOMA PROGNOSTIC STAGE III BREAST CANCER AJCC V8 PROGNOSTIC STAGE III BREAST CANCER AJCC V8 PROGNOSTIC STAGE IIIA BREAST CANCER AJCC V8 PROGNOSTIC STAGE IIIA BREAST CANCER AJCC V8 PROGNOSTIC STAGE IIIB BREAST CANCER AJCC V8 PROGNOSTIC STAGE IIIB BREAST CANCER AJCC V8 PROGNOSTIC STAGE IIIC BREAST CANCER AJCC V8 PROGNOSTIC STAGE IV BREAST CANCER AJCC V8 STAGE III PROSTATE CANCER AJCC V8 STAGE III PROSTATE CANCER AJCC V8 STAGE IIIA PROSTATE CANCER AJCC V8 STAGE IIIA PROSTATE CANCER AJCC V8 STAGE IIIA PROSTATE CANCER AJCC V8 STAGE IIIB PROSTATE CANCER AJCC V8 STAGE IIIB PROSTATE CANCER AJCC V8 STAGE IIIB PROSTATE CANCER AJCC V8 STAGE IIIC PROSTATE CANCER AJCC V8 STAGE IIIC PROSTATE CANCER AJCC V8 STAGE IIIC PROSTATE CANCER AJCC V8 STAGE IV PROSTATE CANCER AJCC V8 STAGE IV PROSTATE CANCER AJCC V8 STAGE IVA PROSTATE CANCER AJCC V8 STAGE IVA PROSTATE CANCER AJCC V8 STAGE IVB PROSTATE CANCER AJCC V8 STAGE IVB PROSTATE CANCER AJCC V8 TRIPLE-NEGATIVE BREAST CARCINOMA UNRESECTABLE SOLID NEOPLASM